@article{d3d3054cb50a4222b041363643a2672f,
title = "Antibiotic Treatment Improves the Efficacy of Oxaliplatin-Based Therapy as First-Line Chemotherapy for Patients with Advanced Gastric Cancer: A Retrospective Study",
abstract = "Purpose: One of the first-line treatment for gastric cancer patients is oxaliplatin, and the efficacy of this chemotherapeutic can be attenuated by the microbiome. In this study, we retrospectively evaluated whether treatment with antibiotics improved the efficacy of oxaliplatin-based chemotherapy in patients with advanced gastric cancer. Patients and Methods: Fifty-four patients were assigned to the antibiotic-treated group and 35 to the antibiotic-untreated group. Results: The response rate of oxaliplatin-based chemotherapy in the antibiotic-treated and antibiotic-untreated groups was 66.7% and 41.4%, respectively (p = 0.038). The median progression-free survival after oxaliplatin-based chemotherapy in the antibiotic-treated and antibiotic-untreated groups was 8.8 and 5.2 months, respectively (hazard ratio = 0.456, 95% confidence interval = 0.254–0.819; p = 0.007, Log rank test). Univariate and multivariate analyses revealed that antibiotic treatment was the only clinical parameter that correlated with the response to oxaliplatin. Conclusion: Antibiotic treatment could be used therapeutically to enhance the efficacy of oxaliplatin-based chemotherapy in patients with advanced gastric cancer.",
keywords = "antibiotics, chemotherapy, gastric cancer, oxaliplatin",
author = "Hiroo Imai and Ken Saijo and Keigo Komine and Reio Ueta and Ryunosuke Numakura and Shonosuke Wakayama and Sho Umegaki and Sakura Hiraide and Yoshufumi Kawamura and Yuki Kasahara and Kota Ohuchi and Masahiro Takahashi and Shin Takahashi and Hidekazu Shirota and Masanobu Takahashi and Chikashi Ishioka",
note = "Funding Information: Chikashi Ishioka has been funded by the Tokyo Cooperative Oncology Group, and obtained financial support from Chugai Pharmaceutical, Ono Pharmaceutical, MSD, Pfizer, AstraZeneca, Bristol-Myers Squibb, Janssen Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical, and is a representative of Tohoku Clinical Oncology Research and Education Society, a specified nonprofit corporation. Also, he reports grants from Japan Agency for Medical Research and Development (AMED), Grants-in-Aid for Scientific Research KAKENHI, Eisai, Sanofi, Tsumura, Novartis, Merck, Yakurt, Asahikasei, Shionogi, Kyowa-Kirin, Ono, Otsuka, Taiho, Daiichi, Chugai, Lilly, Nippon-Kayaku, and Takeda, outside the submitted work. Masanobu Takahashi was the recipient of research funding from Ono Pharmaceutical. Shin Takahashi reports personal fees from Yakult, outside the submitted work. The authors report no other conflicts of interest in this work. Publisher Copyright: {\textcopyright} 2022 Imai et al.",
year = "2022",
doi = "10.2147/CMAR.S353432",
language = "English",
volume = "14",
pages = "1259--1266",
journal = "Cancer Management and Research",
issn = "1179-1322",
publisher = "Dove Medical Press Ltd.",
}
